Welcome to our dedicated page for Avalon Globocare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalon GloboCare Corp. (NASDAQ: ALBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents. These filings describe Avalon as a commercial‑stage company focused on precision diagnostic consumer products, cellular therapy intellectual property, generative AI publishing and software, and commercial real estate operations. Through its SEC reports, Avalon details material events such as acquisitions, financing arrangements, Nasdaq listing matters, and progress on its proposed merger with YOOV Group Holding Limited.
In recent Form 8‑K filings, Avalon has reported the acquisition of RPM Interactive, Inc. through its subsidiary Avalon Quantum AI, LLC, adding a generative AI powered SaaS platform for automated short‑form video creation. Other 8‑K and 8‑K/A filings outline senior secured promissory notes, bridge notes, waivers and amendments, unregistered sales of equity securities, and changes to preferred stock designations, including Series C and Series E preferred stock. Filings also document Nasdaq correspondence regarding compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b) and the company’s steps to address those requirements.
SEC filings further describe Avalon’s Agreement and Plan of Merger with YOOV Group Holding Limited and the related Registration Statement on Form S‑4, which contains a preliminary proxy statement/prospectus. These documents explain the structure of the proposed merger, the conditions to closing, and the anticipated focus on Artificial Intelligence‑as‑a‑Service (AIaaS) solutions following completion. Additional disclosures cover the company’s share issuances, beneficial ownership limitations, and updates on outstanding notes and conversion terms.
On Stock Titan, users can review Avalon’s 8‑K, 8‑K/A, 10‑K, and other SEC filings, while AI‑powered tools help summarize complex sections, highlight key terms, and surface information on topics such as financing, preferred stock features, Nasdaq listing status, and merger‑related disclosures. This makes it easier to understand how Avalon’s precision diagnostics, cellular therapy IP, AI software assets, and capital structure are reflected in its official regulatory record.
Avalon GloboCare Corp. has filed a resale registration covering up to 19,436,278 shares of common stock for existing investors. These consist of 490,197 already-issued shares plus shares underlying pre-funded warrants, Series A-1 and A-2 warrants, and placement agent warrants issued in a February 2026 private placement.
The company will not receive proceeds from investors’ resale of these shares, but could receive about $6.7 million if 18,946,081 warrant shares are fully exercised for cash. Shares outstanding were 8,323,609 as of April 8, 2026 and would be 27,759,887 if all registered warrants are exercised. The filing also highlights a history of substantial losses, a $105.9 million accumulated deficit, minimal cash, and an auditor going-concern warning, underscoring the need for additional capital.
Avalon Globocare Corp. set its 2026 Annual Meeting of Stockholders for June 9, 2026, to be held virtually. Stockholders of record as of May 15, 2026 may vote at the meeting. The company also established April 12, 2026 as the deadline for shareholder proposals and director nominations.
Proposals for inclusion in the company’s proxy materials must meet the requirements of Rule 14a-8 and be received by the Corporate Secretary by April 12, 2026. Other proposals or director nominations must also comply with SEC rules, Delaware law and the company’s Amended and Restated Bylaws, or they will not be considered.
Avalon GloboCare Corp. explains that its shareholders approved several proposals related to the company’s capital structure and financing flexibility, including authorizing the Board to implement a reverse stock split in the future if deemed appropriate. The company states this approval does not mean a reverse stock split is being implemented now and that there is currently no reverse stock split planned.
Avalon describes this authorization as a standard governance measure intended to preserve flexibility as it evaluates strategic and corporate priorities, while emphasizing continued focus on executing its business strategy. The company also highlights that it uses social media channels on Stocktwits, X, Yahoo Finance and Reddit to share public information that may be considered material and encourages interested parties to review updates posted there.
Avalon Globocare Corp. stockholders approved seven proposals at a special meeting where 2,498,866 common shares were represented, constituting a quorum. Approvals covered share issuances tied to July 2025 convertible notes, a December 2025 bridge note with 100,000 commitment shares, and conversion of Series C Convertible Preferred Stock.
Stockholders also approved exchanging 5,000 shares of Series D Convertible Preferred Stock held by the board chairman for 2,074,689 common shares, issuing 450,000 restricted common shares under a consulting agreement, and granting the board authority to implement a reverse stock split between 1-for-2 and 1-for-25 without reducing authorized shares. Adjournment authority, if needed, was also approved.
Avalon GloboCare filed its annual report describing a pivot from legacy biotech and China operations into two main businesses: the Keto Air consumer breathalyzer and the RPM AI-driven short‑form video platform acquired in December 2025. The company posted a net loss of $18,260,976 in 2025, including $17,518,873 from continuing operations, and its auditors raised substantial doubt about its ability to continue as a going concern.
Cash was only $109,091 at December 31, 2025 against a working capital deficit of $12,651,237 and outstanding debt of about $1.1 million, so Avalon plans to raise additional capital and depends on future revenue from Keto Air and the RPM platform, which is still in beta with Phase 2 targeted for Q3 2026. The company also issued Series E preferred stock valued at $19.5 million to buy RPM, faces potential dilution from several preferred series and convertible notes, and must secure shareholder approval and stay within Nasdaq rules to fully convert the new preferred shares.
Avalon GloboCare Corp. completed a private placement, raising approximately $2.8 million in net proceeds from institutional investors through a mix of common stock, pre-funded warrants and Series A-1 and A-2 warrants.
The deal included 490,197 shares of common stock at $0.51 per share, pre-funded warrants to purchase up to 5,882,353 shares, and Series A-1 and A-2 warrants to purchase up to 6,372,550 shares each at an exercise price of $0.51 per share, all subject to specified ownership caps and, for the common warrants, stockholder approval. H.C. Wainwright received cash fees and placement agent warrants for 318,628 shares at $0.6375 per share, and Roth Capital Partners was paid $75,000 as financial advisor.
The company plans to use the net proceeds primarily for operating expenses, working capital, and repayment of certain outstanding debt. Separately, it issued 287,411, 230,739 and 750,522 shares of common stock on February 19, 24 and 26, 2026 upon net exercises of existing warrants, with no cash proceeds received from those exercises.
Avalon Globocare Corp. reported changes to executive and board compensation. On March 4, 2026, the Board approved a cash bonus of $175,000 for Chief Financial Officer Luisa Ingargiola in recognition of her efforts advancing the business and financial position during the 2025 fiscal year.
The Board also increased annual fees payable to lead director Steven Saunders to $95,000 for his service on the Board of Directors. These actions reflect compensation decisions rather than operational or financial performance metrics.
Avalon GloboCare Corp. reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC jointly state beneficial ownership of 490,197 shares of Common Stock, representing 7.0% of the outstanding common stock based on 7,042,348 shares outstanding as of February 27, 2026.
The filing excludes two warrants held by Intracoastal (each exercisable into 490,197 shares) because each warrant is not exercisable until stockholder approval of the issuances and contains a blocker provision limiting exercise to prevent ownership above 4.99%. Without those blocker provisions (and if exercisable), the reporting persons may be deemed to beneficially own 1,470,591 shares.
Avalon GloboCare Corp. is asking stockholders to approve several financing-related actions and a potential reverse stock split at a March 30, 2026 virtual special meeting. Holders of 6,264,740 common shares as of February 17, 2026 can vote.
The Company seeks approval for conversions tied to July 2025 convertible notes, a December 2025 bridge note plus 100,000 commitment shares, and its Series C preferred stock, each needed to comply with Nasdaq Listing Rule 5635(d) because conversions could exceed 20% of prior outstanding shares.
Stockholders are also asked to approve exchanging 5,000 Series D preferred shares held by Chairman Wenzhao Lu for 2,074,689 common shares, issuing 450,000 restricted shares to an advisor, and authorizing a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑25, without reducing authorized common shares, to help maintain Nasdaq listing and potentially broaden investor interest. An adjournment proposal would allow extra time to solicit votes if needed. The Board unanimously recommends voting “FOR” all proposals.